Quantcast

Latest Typical antipsychotic Stories

2009-10-12 17:01:00

EAST HANOVER, N.J., Oct. 12 /PRNewswire-FirstCall/ -- Novartis Pharma AG has entered into an agreement for exclusive US and Canadian rights to Fanapt(TM) (iloperidone), a new oral medication that is approved by the US Food and Drug Administration (FDA) for the acute treatment of adults with schizophrenia. Novartis plans to launch Fanapt in the US in early 2010. As part of the agreement with Vanda Pharmaceuticals Inc., Novartis will have exclusive commercialization rights to the...

2009-10-12 17:00:00

ROCKVILLE, Md., Oct. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults. Fanapt((TM)) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist. The U.S....

2009-09-14 06:00:00

ISTANBUL, Sept. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported final results of a SAPHRIS(R) (asenapine) long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the primary efficacy endpoint, was significantly longer with SAPHRIS than with placebo (P < 0.0001). At the end of the double-blind phase, significantly fewer patients had relapsed with SAPHRIS than with...

2009-08-14 07:30:00

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS(R) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial approval for both of these indications simultaneously....

2009-08-14 06:00:00

KENILWORTH, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS((R)) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial...

2009-07-30 06:30:30

Older diabetic patients who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a new report. The antipsychotic drugs prescribed for older adults with dementia may be associated with adverse effects, including Parkinson's disease symptoms, stroke and diabetes. "The risk of diabetes may be partly related to chronic effects of the weight gain associated with...

2009-05-19 13:56:00

SAN FRANCISCO, May 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder. Results of the study were presented this week at a major medical meeting. Bipolar Disorder is a brain disorder that causes unusual shifts in a person's mood, energy and ability to function. It is often characterized by debilitating mood...

2009-05-19 06:57:00

SAN FRANCISCO, May 19 /PRNewswire/ -- Schizophrenia is one of the most disabling diseases,(1) and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society.(2) According to two new studies, the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment (RLAT) may improve clinical and functional outcomes and reduce rates of rehospitalization among patients with schizophrenia. Results of the studies were presented this...

2009-05-18 12:30:00

Three-year data show olanzapine LAI safety findings consistent with oral olanzapine except for injection-related events INDIANAPOLIS, May 18 /PRNewswire-FirstCall/ -- Eli Lilly and Company presented today data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation that combines the atypical antipsychotic Zyprexa(R) (olanzapine) with...

2009-05-06 16:53:29

The U.S. Food and Drug Administration has approved Fanapt tablets to treat adults with schizophrenia, a chronic, severe and disabling brain disorder. Schizophrenia can be a devastating illness requiring lifelong treatment and therapy, said Dr. Thomas Laughren, director of the FDA's division of psychiatry products. Medications for schizophrenia can ease many symptoms, allowing people to live more independent lives. The federal agency said Fanapt (iloperidone) is included in the atypical...